Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sapropterin
Drug ID BADD_D01987
Description Sapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of tryptophan to 5-hydroxytryptophan via tryptophan hydroxylase.
Indications and Usage For the treatment of tetrahydrobiopterin (BH4) deficiency.
Marketing Status approved; investigational
ATC Code A16AX07
DrugBank ID DB00360
KEGG ID D08505
MeSH ID C003402
PubChem ID 135398654
TTD Drug ID D0Q9YT
NDC Product Code Not Available
UNII EGX657432I
Synonyms sapropterin | 6R-BH4 | tetrahydrobiopterin | 5,6,7,8-erythro-tetrahydrobiopterin | tetrahydro-6-biopterin | phenylalanine hydroxylase cofactor | 5,6,7,8-tetrahydrodictyopterin | D-threo-tetrahydrobiopterin | 5,6,7,8-tetrahydro-L-erythrobiopterin | sapropterin dihydrochloride | 2,4,5-trihydroxybutyrophenone | THBP | 1-butanone, 1-(2,4,5-trihydroxyphenyl) | trihydroxybutyrophenone | 2',4',5'-trihydroxybutyrophenone | 6R-L-erythro-5,6,7,8-tetrahydrobiopterin | 5,6,7,8-tetrahydrobiopterin, (S-(R*,S*))-isomer | 5,6,7,8-tetrahydrobiopterin | kuvan
Chemical Information
Molecular Formula C9H15N5O3
CAS Registry Number 62989-33-7
SMILES CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pyrexia08.05.02.0030.028462%
Rash23.03.13.001--Not Available
Respiration abnormal22.02.01.0410.009487%Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Rhinorrhoea22.12.03.0210.014662%
Seizure17.12.03.0010.027599%
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Vertigo17.02.12.002; 04.04.01.0030.014662%
Vomiting07.01.07.0030.040968%
Post procedural haemorrhage24.07.01.014; 12.02.05.004--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal stiffness15.03.05.0270.014662%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Urine output increased13.13.03.002--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.0020.004312%Not Available
Abnormal behaviour19.01.01.0010.073310%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.029324%
Low birth weight baby18.04.02.0030.006469%Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Foetal growth restriction18.03.01.0020.004312%
Attention deficit hyperactivity disorder19.21.04.0040.046142%Not Available
Behaviour disorder19.01.01.0050.038811%Not Available
Therapy non-responder08.06.01.0630.131959%Not Available
Treatment noncompliance12.09.02.006; 08.06.01.0670.009487%Not Available
The 3th Page    First    Pre   3    Total 3 Pages